Organon & Co.
For the period ended Sep 30, 2026. Filed Oct 30, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 30, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Earnings per Share
- Earnings per Share (“EPS”)
The calculations of basic and diluted EPS are as follows:
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| ($ in millions and shares in thousands, except per share amounts) | 2026 | 2025 | 2026 | 2025 |
| Net income | $164 | $160 | $418 | $392 |
| Basic weighted average number of shares outstanding | 262,616 | 259,975 | 261,874 | 259,266 |
| Stock awards and equity units (share equivalent) | 9,768 | 678 | 6,711 | 1,345 |
| Diluted weighted average common shares outstanding | 272,384 | 260,653 | 268,585 | 260,611 |
| EPS: | ||||
| Basic | $0.62 | $0.61 | $1.60 | $1.51 |
| Diluted | $0.60 | $0.61 | $1.56 | $1.50 |
| Anti-dilutive shares excluded from the calculation of EPS | 6,781 | 16,238 | 6,765 | 15,871 |
Diluted EPS was computed using the treasury stock method for stock option awards, performance share units, and restricted share units. The computation of diluted EPS excludes the effect of the potential exercise of stock-based awards when the effect of the potential exercise would be anti-dilutive.
-11-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.